Ikena Oncology Inc. (IKNA) NASDAQ

$3.29 -0.06 (-1.79%)

Market Cap: $118.98M

As of 05/25/22 04:00 PM EDT. Market closed.

(IKNA)

Ikena Oncology Inc. (IKNA) NASDAQ

$3.29 -0.06 (-1.79%)

Market Cap: $118.98M

As of 05/25/22 04:00 PM EDT. Market closed.

Ikena Oncology is a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Ikena is advancing five programs that include four product candidates in either clinical development or IND-enabling studies: IK-930, a TEAD inhibitor targeting the Hippo signaling pathway; an ERK5 inhibitor program targeting the KRAS ... read more

Ikena Oncology is a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Ikena is advancing five programs that include four product candidates in either clinical development or IND-enabling studies: IK-930, a TEAD inhibitor targeting the Hippo signaling pathway; an ERK5 inhibitor program targeting the KRAS signaling pathway; IK-175, an AHR antagonist; IK-412, a kynurenine-degrading enzyme; and IK-007, an EP4 receptor antagonist. Ikena has entered into a global strategic collaboration with Bristol-Myers Squibb Company for its IK-175 and IK-412 programs. read less

COMPANY PROFILE
Sector
Manufacturing
Industry
Medicinal and Botanical Manufacturing
URL
Address
.
Sector
Manufacturing
Industry
Medicinal and Botanical Manufacturing
Full Time Employees
33
Address
.
PRICE CHART
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
KEY STATS
Open
$0
Previous Close
$3.35
Days Range
$3.22 - $3.40
52 week range
$2.83 - $20.37
Volume
73,182
Avg. Volume (30 days)
217,138
Market Cap
$118.98M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
36,163,291
Open
$0
Previous Close
$3.35
Days Range
$3.22 - $3.40
52 week range
$2.83 - $20.37
Volume
73,182
Avg. Volume (30 days)
217,138
Market Cap
$118.98M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
36,163,291

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR IKENA ONCOLOGY INC
Owner Relationship Date Transaction Cost # Shares Value($) Total Shares Form 4
Tessier Maude Chief Business Officer Jan 18, 2022 Option Exercise $3.54 71,786 253,800 100,578 Jan 20, 2022, 04:30 PM
Zhang Xiaoyan Michelle Chief Scientific Officer Jan 10, 2022 Option Exercise $2.15 36 77 44,511 Jan 12, 2022, 07:25 PM
Zhang Xiaoyan Michelle Chief Scientific Officer Jan 11, 2022 Option Exercise $2.15 964 2,069 45,439 Jan 12, 2022, 07:25 PM
Zhang Xiaoyan Michelle Chief Scientific Officer Jan 10, 2022 Sale $12.00 36 432 44,475 Jan 12, 2022, 07:25 PM
Zhang Xiaoyan Michelle Chief Scientific Officer Jan 11, 2022 Sale $12.00 964 11,568 44,475 Jan 12, 2022, 07:25 PM
Zhang Xiaoyan Michelle Chief Scientific Officer Dec 10, 2021 Option Exercise $2.15 1,000 2,146 45,475 Dec 14, 2021, 08:48 PM
Zhang Xiaoyan Michelle Chief Scientific Officer Dec 10, 2021 Sale $14.76 1,000 14,760 44,475 Dec 14, 2021, 08:48 PM
FORMELA JEAN FRANCOIS Director Mar 30, 2021 Buy $16.00 125,000 2,000,000 874,634 Dec 14, 2021, 08:29 PM
FORMELA JEAN FRANCOIS Director Dec 10, 2021 Sale $15.03 11,989 180,195 1,256,224 Dec 14, 2021, 08:29 PM
FORMELA JEAN FRANCOIS Director Dec 14, 2021 Sale $14.00 5,959 83,426 1,241,935 Dec 14, 2021, 08:29 PM
FORMELA JEAN FRANCOIS Director Dec 13, 2021 Sale $14.64 8,330 121,951 1,247,894 Dec 14, 2021, 08:29 PM
Atlas Venture Fund XI, L.P. 10% Owner Mar 30, 2021 Buy $16.00 125,000 2,000,000 874,634 Dec 14, 2021, 08:27 PM
Atlas Venture Fund XI, L.P. 10% Owner Dec 14, 2021 Sale $14.00 5,959 83,426 1,241,935 Dec 14, 2021, 08:27 PM
Atlas Venture Fund XI, L.P. 10% Owner Dec 13, 2021 Sale $14.64 8,330 121,951 1,247,894 Dec 14, 2021, 08:27 PM
Atlas Venture Fund XI, L.P. 10% Owner Dec 10, 2021 Sale $15.03 11,989 180,195 1,256,224 Dec 14, 2021, 08:27 PM
Bonita David P Director Mar 30, 2021 Buy $16.00 423,400 6,774,400 1,845,872 Apr 14, 2021, 06:29 PM
ORBIMED ADVISORS LLC Director Mar 30, 2021 Buy $16.00 423,400 6,774,400 1,845,872 Apr 13, 2021, 06:36 PM
Stampacchia Otello Director Mar 30, 2021 Option Exercise $16.00 450,000 7,200,000 2,249,123 Apr 01, 2021, 06:16 PM
Bonita David P Director Mar 30, 2021 Buy $16.00 423,400 6,774,400 2,191,425 Apr 01, 2021, 06:14 PM
ORBIMED ADVISORS LLC Director Mar 30, 2021 Buy $16.00 423,400 6,774,400 2,191,425 Apr 01, 2021, 06:13 PM
Load More Insider Transactions
Buy Sale Option Exercise
Owner Relationship Date Value($)
Tessier Maude Chief Business Officer 01/18/2022 253,800
Zhang Xiaoyan Michelle Chief Scientific Officer 01/10/2022 77
Zhang Xiaoyan Michelle Chief Scientific Officer 01/11/2022 2,069
Zhang Xiaoyan Michelle Chief Scientific Officer 01/10/2022 432
Zhang Xiaoyan Michelle Chief Scientific Officer 01/11/2022 11,568
Zhang Xiaoyan Michelle Chief Scientific Officer 12/10/2021 2,146
Zhang Xiaoyan Michelle Chief Scientific Officer 12/10/2021 14,760
FORMELA JEAN FRANCOIS Director 03/30/2021 2,000,000
FORMELA JEAN FRANCOIS Director 12/10/2021 180,195
FORMELA JEAN FRANCOIS Director 12/14/2021 83,426
FORMELA JEAN FRANCOIS Director 12/13/2021 121,951
Atlas Venture Fund XI, L.P. 10% Owner 03/30/2021 2,000,000
Atlas Venture Fund XI, L.P. 10% Owner 12/14/2021 83,426
Atlas Venture Fund XI, L.P. 10% Owner 12/13/2021 121,951
Atlas Venture Fund XI, L.P. 10% Owner 12/10/2021 180,195
Bonita David P Director 03/30/2021 6,774,400
ORBIMED ADVISORS LLC Director 03/30/2021 6,774,400
Stampacchia Otello Director 03/30/2021 7,200,000
Bonita David P Director 03/30/2021 6,774,400
ORBIMED ADVISORS LLC Director 03/30/2021 6,774,400
Load More Insider Transactions